Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial - PubMed
5 hours ago
- #Randomized Trial
- #Proton Therapy
- #Oropharyngeal Cancer
- The TORPEdO trial compared intensity-modulated proton therapy (IMPT) with intensity-modulated radiation therapy (IMRT) for oropharyngeal squamous cell carcinoma.
- Primary endpoints included gastrostomy-tube dependence or severe weight loss and quality of life scores at 12 months.
- 205 patients were randomized (136 to IMPT, 69 to IMRT), with similar outcomes in both groups for gastrostomy-tube dependence and severe weight loss.
- Quality of life scores (UW-QoL physical composite) were comparable between IMPT (78.3) and IMRT (77.1) groups at 12 months.
- Serious adverse events were noted, including acute kidney injury and thromboembolism, with no treatment-related deaths.
- At 24 months, freedom from loco-regional recurrence and overall survival rates were similar between groups (94% vs 97% and 95% vs 95%, respectively).
- IMPT did not show significant superiority over IMRT in late physical quality of life, local control, or survival, supporting IMRT as the standard care where IMPT is not routine.